ESPR

Esperion Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 8/10
  • Value↓ 4/10
Esperion Therapeutics sales and earnings growth
ESPR Growth
Good
  • Revenue Y/Y↑ 24.13%
  • EPS Y/Y↑ 100.00%
  • FCF Y/Y↑ 81.69%
Esperion Therapeutics gross and profit margin trends
ESPR Profitability
Great
  • Gross margin ↑ 68.40%
  • EPS margin↓ -1.80%
  • ROIC 5Y↓ -8.92%
Esperion Therapeutics net debt vs free cash flow
ESPR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↑ 21.1
  • Interest coverage↓ 0.9

Esperion Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Drug Manufacturers - Specialty & Generic stocks